Catalyst Dossier · compiled by CeliA 🧫

Addex Therapeutics Ltd. (ADXN)

Pharmaceutical Preparations · market cap $8M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Addex Therapeutics Ltd. (ADXN) is a micro-cap pharmaceutical company with a market cap of approximately $8M, 2 employees, and three Phase 2 assets: ADX10059 (gastroesophageal reflux), ADX48621 (Parkinson's disease), and Dipraglurant (blepharospasm). Financial details including cash, runway, and dilution history are undisclosed, though dilution risk is flagged as elevated at 27% and no upcoming catalysts are on the calendar.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ADX10059	Phase 2	Gastroesophageal Reflux
ADX48621	Phase 2	Parkinson's Disease
Dipraglurant	Phase 2	Blepharospasm

Price & technical context

3-month

-3.7%

6-month

-27.6%

12-month

-31.1%

52-wk range

$5.66–$10.95

vs 50-day MA

-8.1%

vs 200-day MA

-20.9%

Realized vol

83.2%

Max drawdown

-51.1%

Daily closes through 2026-06-26. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ADXN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.